keyword
MENU ▼
Read by QxMD icon Read
search

rheumatol arthritis

keyword
https://www.readbyqxmd.com/read/27785909/errors-in-table-3-of-the-article-by-domsic-et-al-arthritis-rheumatol-april-2016
#1
(no author information available yet)
No abstract text is available yet for this article.
November 2016: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/27558405/financial-disclosure-information-on-one-author-in-the-article-by-cartin-ceba-et-al-arthritis-rheumatol-june-2016
#2
(no author information available yet)
No abstract text is available yet for this article.
September 2016: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/27107516/corrigendum-to-risk-of-infection-with-biologic-antirheumatic-therapies-in-patients-with-rheumatoid-arthritis-best-pract-res-clin-rheumatol-29-2-2015-290-305
#3
Manjari Lahiri, William G Dixon
No abstract text is available yet for this article.
December 2015: Best Practice & Research. Clinical Rheumatology
https://www.readbyqxmd.com/read/27023361/financial-disclosure-information-inadvertently-omitted-by-the-journal-in-the-editorial-by-sattar-and-mcinnes-arthritis-rheumatol-march-2016
#4
(no author information available yet)
No abstract text is available yet for this article.
April 2016: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/26808829/errata
#5
(no author information available yet)
Errors in Table 3 and 4 of the Article by Solomon et al (Arthritis Rheumatol, August 2015).
February 2016: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/26808828/errata
#6
(no author information available yet)
Misspelled Author Name in the Article by Neogi et al (Arthritis Rheumatol, October 2015).
February 2016: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/26508467/amended-95-confidence-intervals-in-tables-in-the-article-by-jani-et-al-arthritis-rheumatol-august-2015
#7
(no author information available yet)
No abstract text is available yet for this article.
November 2015: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/26340306/erratum
#8
Heidi Jacobe, Chul Ahn, Frank C Arnett, John D Reveille
In the article by Jacobe et al published in the November 2014 issue of Arthritis & Rheumatology (pages 3170-3177), a row listing the (nonexistent) allele DQA1*03:00 was inadvertently included in Tables 3, 5, and 6, as the result of a typographical error.
March 2015: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/26309053/misidentified-band-in-figure-in-the-article-by-zhang-et-al-arthritis-rheumatol-march-2015
#9
(no author information available yet)
No abstract text is available yet for this article.
September 2015: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/26309052/incorrect-figure-in-the-article-by-wang-et-al-arthritis-rheumatol-january-2014
#10
(no author information available yet)
No abstract text is available yet for this article.
September 2015: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/26174879/comorbidity-indices-for-clinical-trials-adaptation-of-two-existing-indices-for-use-with-the-freedom-trial-in-women-with-postmenopausal-osteoporosis
#11
RANDOMIZED CONTROLLED TRIAL
S L Silverman, A Wang, L Cheng, Y Yang, C Libanati, M Geller, A Grauer, M Nevitt, D Revicki, H N Viswanathan
UNLABELLED: Two comorbidity indices were adapted for use in the FREEDOM trial and significantly correlated with the number of medications and impaired health status at baseline. The indices have applications for the analysis of clinical trial data and would allow for the appropriate adjustment of comorbidities when evaluating clinical trial outcomes. INTRODUCTION: The purpose of this study is to adapt two published comorbidity indices for use with the FREEDOM clinical trial evaluating postmenopausal women with osteoporosis...
January 2016: Osteoporosis International
https://www.readbyqxmd.com/read/26013245/errors-relating-to-study-controls-and-criteria-naming-in-the-editorial-by-wolfe-arthritis-rheumatol-february-2015
#12
(no author information available yet)
No abstract text is available yet for this article.
June 2015: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/25227901/clinical-trials-documenting-the-efficacy-of-low-dose-glucocorticoids-in-rheumatoid-arthritis
#13
Theodore Pincus, Maurizio Cutolo
Twelve clinical trials have documented that prednisone or prednisolone in doses of 10 mg/day or less is efficacious to improve function, maintain status and/or slow radiographic progression in patients with rheumatoid arthritis (RA). An early trial reported by de Andrade et al. [Ann Rheum Dis 1964;23:158-162] in 1964 indicated that 5 mg of prednisolone at night was preferred to 5 mg of prednisone in the morning. Harris et al. [J Rheumatol 1983;10:713-721] documented the efficacy of 5 mg/day of prednisone in a non-double-blind trial in 1983...
2015: Neuroimmunomodulation
https://www.readbyqxmd.com/read/24634205/longterm-safety-and-effectiveness-of-the-anti-interleukin-6-receptor-monoclonal-antibody-tocilizumab-in-patients-with-systemic-juvenile-idiopathic-arthritis-in-japan
#14
RANDOMIZED CONTROLLED TRIAL
Shumpei Yokota, Tomoyuki Imagawa, Masaaki Mori, Takako Miyamae, Syuji Takei, Naomi Iwata, Hiroaki Umebayashi, Takuji Murata, Mari Miyoshi, Minako Tomiita, Norihiro Nishimoto, Tadamitsu Kishimoto
OBJECTIVE: To assess the longterm safety and effectiveness of tocilizumab (TCZ) in systemic-onset juvenile idiopathic arthritis (sJIA). METHODS: The longterm extension phase of 2 pivotal studies (phase II with 11 patients and phase III with 56 patients) in patients with active sJIA was analyzed. Patients received open-label TCZ (8 mg/kg, every 2 weeks) without concomitant use of disease-modifying antirheumatic drugs. RESULTS: In total, 67 patients were enrolled...
April 2014: Journal of Rheumatology
https://www.readbyqxmd.com/read/24158775/glp-1-receptor-agonist-induced-polyarthritis-a-case-report
#15
Maria Luisa Ambrosio, Matteo Monami, Lavinia Sati, Niccolò Marchionni, Mauro Di Bari, Edoardo Mannucci
Occasional cases of bilateral, symmetrical, seronegative polyarthritis have been reported in patients treated with dipeptidyl peptidase-4 inhibitors (Crickx et al. in Rheumatol Int, 2013). We report here a similar case observed during treatment with a GLP-1 receptor agonist. A 42-year-old man with type 2 diabetes treated with metformin 1,500 mg/day and liraglutide 1.8 mg/day. After 6 months from the beginning of treatment, the patient complained of bilateral arthralgia (hands, feet, ankles, knees, and hips)...
August 2014: Acta Diabetologica
https://www.readbyqxmd.com/read/23955767/a-case-of-infliximab-induced-lupus-in-a-patient-with-ankylosing-spondylitis-is-it-safe-switch-to-another-anti-tnf-%C3%AE-agent
#16
REVIEW
Tânia Santiago, Mariana Galante Santiago, João Rovisco, Cátia Duarte, Armando Malcata, José António Pereira da Silva
Anti-TNF-α therapies are the latest class of medications found to be associated with drug-induced lupus, a distinctive entity known as anti-TNF-α-induced lupus (ATIL) (Williams et al., Rheumatology (Oxford) 48:716-20, 2009; De Rycke et al., Lupus 14:931-7, 2005; De Bandt et al., Clin Rheumatol 22:56-61, 2003). With the widespread use of these agents, it is likely that the incidence of ATIL will increase. The onset of ATIL in patients with rheumatoid arthritis and Crohn's disease has been described, but the literature regarding the occurrence of this entity in patients with ankylosing spondylitis (AS) is scarce (De Bandt et al...
December 2013: Clinical Rheumatology
https://www.readbyqxmd.com/read/23216170/chronic-diseases-in-the-european-union-the-prevalence-and-health-cost-implications-of-chronic-pain
#17
REVIEW
R M Leadley, N Armstrong, Y C Lee, A Allen, J Kleijnen
The objective of this study was to assess recent data on the prevalence of chronic pain as part of chronic diseases; the prevalence of chronic pain as a chronic condition in its own right; the costs attributed to chronic pain; and the European Union (EU) policies to addressing chronic pain. Recent literature was reviewed for data on the prevalence and cost implications of chronic pain in the EU. Following on from an earlier systematic review, 8 databases were searched for prevalence and 10 for cost information from 2009 to 2011 and relevant EU organizations were contacted...
December 2012: Journal of Pain & Palliative Care Pharmacotherapy
https://www.readbyqxmd.com/read/21586803/-dissemination-of-medical-knowledge-to-the-public-in-iceland-by-a-country-doctor-1782-1834
#18
Orn Bjarnason
Jón Pétursson (1733-1801) was an apprentice af the first Chief Medical Officer of Iceland. In 1765 Pétursson enrolled in the Medical Faculty at the University of Copenhagen. In 1769 with the Faculties approval he published a monograph on the so called Icelandic Scurvy. In 1770-71 Pétursson served as ship's surgeon in the Royal Danish Navy on an expedition to the Mediterranean. In 1772-1775 he served as an assistant to the Chief Medical Officer and the newly appointed apothecary, who shared premises at Nes, Reykjavík...
May 2011: Læknablađiđ
https://www.readbyqxmd.com/read/20195881/spontaneous-pneumomediastinum-secondary-to-refractory-dermatomyositis-successfully-treated-with-rituximab
#19
Martin A Lee, David G Hutchinson
Spontaneous pneumomediastinum has been described in patients with dermatomyositis (DM) and polymyositis (Korkmaz et al., Rheumatology 40:476-478, 2001; Maruoka et al., Mod Rheumatol 16:55-57, 2006; Kono et al., Ann Rheum Dis 59:372-376, 2000; Neves et al., Clin Rheumatol 26:105-107, 2007). Literature reviews suggest that this complication has a mortality of between 27% and 41% ( Kono et al., Ann Rheum Dis 59:372-376, 2000; Neves et al., Clin Rheumatol 26:105-107, 2007; Goff et al., Arthritis Rheum 61:108-118, 2009)...
August 2010: Clinical Rheumatology
https://www.readbyqxmd.com/read/20087751/guidelines-on-the-use-of-etanercept-for-juvenile-idiopathic-arthritis-in-japan
#20
REVIEW
Shumpei Yokota, Masaaki Mori, Tomoyuki Imagawa, Takuji Murata, Minako Tomiita, Yasuhiko Itoh, Satoshi Fujikawa, Syuji Takei
Etanercept is a dimeric fusion protein consisting of the extracellular domain of human tumor necrosis factor receptor II (TNFR II, molecular weight 75 kDa) coupled to the Fc region of human immunoglobulin (IgG1). It is produced by recombinant DNA technology by first introducing the gene into Chinese hamster ovarian cells and then purifying the protein from the culture supernatant. The mechanism of action of etanercept consists of binding to serum TNF-alpha and lymphotoxin (LT)-alpha (TNF-beta), which prevents TNF-alpha and LT-alpha from binding to the TNF-alpha receptor on the plasma membrane of the target cell...
April 2010: Modern Rheumatology
keyword
keyword
73099
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"